HOUSTON / Nov 01, 2023 / Business Wire / U.S. Physical Therapy, Inc. ("USPH" or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention (“IIP”) services, today announced the acquisition of an IIP services and ergonomics software business by one of its two primary IIP companies, Briotix Health Limited Partnership (“Briotix”). In addition to increasing its IIP services business, the newly created ergonomics software provides an exciting new solution to add to Briotix’s offerings to existing and potential customers.
Briotix purchased all of the IIP services business and a 55% equity interest in the ergonomics software business for a total purchase price of approximately $4.0 million. The combined businesses currently generate approximately $2.6 million in annual revenues.
Chris Reading, Chief Executive Officer, said, “The founders of the business, whom we have known for a good while, are of outstanding character and ability, and will be a great addition to our very capable Briotix team. We are particularly excited about the growth potential of the software business which will enable us to serve an even broader audience relating to their ergonomic program needs.”
About U.S. Physical Therapy, Inc.
Founded in 1990, U.S. Physical Therapy, Inc. operates 675 outpatient physical therapy clinics in 42 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 42 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.
More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.
Last Trade: | US$87.00 |
Daily Change: | -2.06 -2.31 |
Daily Volume: | 78,078 |
Market Cap: | US$1.310B |
December 02, 2024 November 12, 2024 November 05, 2024 October 07, 2024 September 03, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load